Mylan-Biocon's Biosimilar Cancer Drug Comparable To Roche's Herceptin: Study

Breast cancer medicine MYL-1401O, the proposed biosimilar Trastuzumab co-developed by drug major Mylan N.V. and its Indian partner Biocon Ltd., is comparable to Roche Holding AG's branded Trastuzumab, a study, dubbed HERITAGE, confirmed. Trastuzumab, sold under the brand name Herceptin, is indicated for the treatment of HER2-positive metastatic breast cancer patients.

from RTT - Biotech http://ift.tt/1UsMIF0
via IFTTT